Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
73.04 (1y: +41%)
Market Cap 39.53 B P/E(ttm) 17.80
Enterprise Value 42.71 B P/B 5.70
BAX- NYSE (USA)
Baxter International Inc.
  • Currently 4.5/5
Business Predictability Rank: 4.5-Star
Back Testing Results:
Average gain of all 4.5-Star stocks: 10.6% per year.
% of Stocks that are in still loss if held for 10yrs: 10%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$73.04
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.551
BAX's Cash to Debt is ranked lower than
72% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.43 vs. BAX: 0.551 )
BAX' s 10-Year Cash to Debt Range
Min: 0.2   Max: 0.89
Current: 0.55
0.2
0.89
Equity to Asset 0.178
BAX's Equity to Asset is ranked lower than
69% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.47 vs. BAX: 0.178 )
BAX' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.31
Current: 0.18
0.07
0.31
Interest Coverage 32.4
BAX's Interest Coverage is ranked lower than
51% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.10 vs. BAX: 32.4 )
BAX' s 10-Year Interest Coverage Range
Min: 6   Max: 99
Current: 32.4
6
99
F-Score: 6
Z-Score: 3.91
M-Score: -2.7
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 19.90
BAX's Operating margin (%) is ranked higher than
88% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. BAX: 19.90 )
BAX' s 10-Year Operating margin (%) Range
Min: 6.4   Max: 22.9
Current: 19.9
6.4
22.9
Net-margin (%) 16.4
BAX's Net-margin (%) is ranked higher than
86% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.30 vs. BAX: 16.4 )
BAX' s 10-Year Net-margin (%) Range
Min: 4.1   Max: 17.6
Current: 16.4
4.1
17.6
ROE (%) 33.5
BAX's ROE (%) is ranked higher than
96% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BAX: 33.5 )
BAX' s 10-Year ROE (%) Range
Min: 10.5   Max: 33.8
Current: 33.5
10.5
33.8
ROA (%) 11.4
BAX's ROA (%) is ranked higher than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BAX: 11.4 )
BAX' s 10-Year ROA (%) Range
Min: 2.7   Max: 13.1
Current: 11.4
2.7
13.1
ROC (Joel Greenblatt) (%) 36.70
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.00 vs. BAX: 36.70 )
BAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.3   Max: 43
Current: 36.7
11.3
43
Revenue Growth (%) 5.7
BAX's Revenue Growth (%) is ranked higher than
71% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. BAX: 5.7 )
BAX' s 10-Year Revenue Growth (%) Range
Min: 1.8   Max: 6.6
Current: 5.7
1.8
6.6
EBITDA Growth (%) 2.6
BAX's EBITDA Growth (%) is ranked higher than
78% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. BAX: 2.6 )
BAX' s 10-Year EBITDA Growth (%) Range
Min: -8   Max: 21.1
Current: 2.6
-8
21.1
EPS Growth (%) 3.9
BAX's EPS Growth (%) is ranked higher than
78% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.15 vs. BAX: 3.9 )
BAX' s 10-Year EPS Growth (%) Range
Min: -10.9   Max: 42.7
Current: 3.9
-10.9
42.7
ยป BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BAX Guru Trades in Q2 2012

Chuck Royce 3,650 sh (New)
John Hussman 501,000 sh (New)
Paul Tudor Jones 12,700 sh (New)
Steven Cohen 395,526 sh (+1364.97%)
Jim Simons 2,244,300 sh (+486.59%)
Ray Dalio 105,750 sh (+249.59%)
Joel Greenblatt 15,013 sh (+80.81%)
Manning & Napier Advisors, Inc 295,205 sh (+17.09%)
Mario Gabelli 417,350 sh (+15.56%)
Vanguard Health Care Fund 3,900,000 sh (+5.41%)
Robert Olstein 139,000 sh (+2.96%)
Bill Frels 1,795,593 sh (+2.38%)
James Barrow 20,243,460 sh (+1.14%)
Jeff Auxier 22,832 sh (+0.52%)
Diamond Hill Capital 2,058,401 sh (+0.08%)
Murray Stahl 4,372 sh (unchged)
Dodge & Cox 5,648 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Jean-Marie Eveillard 1,224,000 sh (unchged)
Bill Nygren 1,103,000 sh (unchged)
Ken Fisher Sold Out
RS Investment Management Sold Out
John Buckingham 99,611 sh (-0.19%)
Tweedy Browne 2,549,273 sh (-1.01%)
Pioneer Investments 1,438,462 sh (-11.33%)
Jeremy Grantham 639,636 sh (-15.3%)
Scott Black 21,271 sh (-23.13%)
John Paulson 2,700,000 sh (-50%)
Chris Davis 1,001,431 sh (-73.8%)
John Rogers 50,576 sh (-86.78%)
» More
Q3 2012

BAX Guru Trades in Q3 2012

Meridian Funds 8,600 sh (New)
Signature Select Canadian Fund 117,400 sh (+96.32%)
Jeremy Grantham 678,705 sh (+6.11%)
Pioneer Investments 1,477,342 sh (+2.7%)
Manning & Napier Advisors, Inc 298,667 sh (+1.17%)
Bill Frels 1,802,634 sh (+0.39%)
Bill Nygren 1,103,000 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
John Rogers 50,576 sh (unchged)
Murray Stahl 4,372 sh (unchged)
Jeff Auxier 22,832 sh (unchged)
Dodge & Cox 5,648 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Paulson Sold Out
Chuck Royce Sold Out
James Barrow 20,232,185 sh (-0.06%)
Tweedy Browne 2,525,617 sh (-0.93%)
Jean-Marie Eveillard 1,208,500 sh (-1.27%)
Scott Black 20,991 sh (-1.32%)
Vanguard Health Care Fund 3,800,000 sh (-2.56%)
Diamond Hill Capital 1,976,514 sh (-3.98%)
John Buckingham 93,828 sh (-5.81%)
Mario Gabelli 387,950 sh (-7.04%)
Robert Olstein 120,000 sh (-13.67%)
Joel Greenblatt 10,498 sh (-30.07%)
Ray Dalio 62,251 sh (-41.13%)
John Hussman 251,000 sh (-49.9%)
Paul Tudor Jones 5,600 sh (-55.91%)
Jim Simons 80,500 sh (-96.41%)
Chris Davis 7,713 sh (-99.23%)
Steven Cohen 1,357 sh (-99.66%)
» More
Q4 2012

BAX Guru Trades in Q4 2012

Steven Cohen 28,300 sh (+1985.48%)
Jim Simons 638,800 sh (+693.54%)
Bill Nygren 1,153,000 sh (+4.53%)
Tweedy Browne 2,603,884 sh (+3.1%)
Jean-Marie Eveillard 2,058 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Vanguard Health Care Fund 3,500,000 sh (unchged)
Meridian Funds 8,600 sh (unchged)
Jeremy Grantham 1,028,948 sh (unchged)
Jeff Auxier 22,832 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
John Buckingham 92,945 sh (-0.94%)
Bill Frels 1,785,550 sh (-0.95%)
James Barrow 19,834,801 sh (-1.96%)
Scott Black 20,521 sh (-2.24%)
Diamond Hill Capital 1,877,063 sh (-5.03%)
Mario Gabelli 361,950 sh (-6.7%)
Vanguard Health Care Fund 3,500,000 sh (-7.89%)
Manning & Napier Advisors, Inc 267,326 sh (-10.49%)
Jean-Marie Eveillard 984,900 sh (-18.5%)
Paul Tudor Jones 4,300 sh (-23.21%)
John Rogers 38,276 sh (-24.32%)
Murray Stahl 3,172 sh (-27.45%)
Chris Davis 5,495 sh (-28.76%)
Dodge & Cox 3,582 sh (-36.58%)
Robert Olstein 72,000 sh (-40%)
Pioneer Investments 722,698 sh (-51.08%)
John Hussman 1,750 sh (-99.3%)
» More
Q1 2013

BAX Guru Trades in Q1 2013

John Hussman 452,950 sh (+25782.9%)
Jim Simons 987,200 sh (+54.54%)
Jeremy Grantham 1,416,548 sh (+37.67%)
Murray Stahl 4,272 sh (+34.68%)
Bill Nygren 1,253,000 sh (+8.67%)
Jeff Auxier 22,981 sh (+0.65%)
Tweedy Browne 2,608,989 sh (+0.2%)
Chris Davis 5,495 sh (unchged)
John Rogers 38,276 sh (unchged)
Dodge & Cox 3,582 sh (unchged)
Vanguard Health Care Fund 3,500,000 sh (unchged)
Meridian Funds 8,600 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Jean-Marie Eveillard 2,000 sh (unchged)
Bill Frels 1,776,452 sh (-0.51%)
John Buckingham 92,303 sh (-0.69%)
Diamond Hill Capital 1,862,474 sh (-0.78%)
Pioneer Investments 713,961 sh (-1.21%)
Manning & Napier Advisors, Inc 253,274 sh (-5.26%)
James Barrow 18,049,024 sh (-9%)
Jean-Marie Eveillard 884,900 sh (-10.15%)
Robert Olstein 63,000 sh (-12.5%)
Mario Gabelli 302,650 sh (-16.38%)
Paul Tudor Jones 2,900 sh (-32.56%)
Steven Cohen 9,325 sh (-67.05%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Add 25782.9%1.2%$66.42 - $72.64 $ 73.046%452950
John Hussman 2012-12-31 Reduce -99.3%0.36%$60.47 - $68.81 $ 73.0414%1750
Tweedy Browne 2012-12-31 Add 3.1%0.15%$60.47 - $68.81 $ 73.0414%2603884
Ray Dalio 2012-12-31 Sold Out 0.05%$60.47 - $68.81 $ 73.0414%0
Joel Greenblatt 2012-12-31 Sold Out 0.04%$60.47 - $68.81 $ 73.0414%0
Dodge & Cox 2012-12-31 Reduce -36.58%$60.47 - $68.81 $ 73.0414%3582
John Paulson 2012-09-30 Sold Out 1.2%$53.37 - $61 $ 73.0426%0
John Hussman 2012-09-30 Reduce -49.9%0.25%$53.37 - $61 $ 73.0426%251000
Ray Dalio 2012-09-30 Reduce -41.13%0.03%$53.37 - $61 $ 73.0426%62251
Joel Greenblatt 2012-09-30 Reduce -30.07%0.02%$53.37 - $61 $ 73.0426%10498
Meridian Funds 2012-09-30 New Buy0.02%$53.37 - $61 $ 73.0426%8600
John Paulson 2012-06-30 Reduce -50%1.1%$49.26 - $60.16 $ 73.0436%2700000
John Hussman 2012-06-30 New Buy0.5%$49.26 - $60.16 $ 73.0436%501000
Ray Dalio 2012-06-30 Add 249.59%0.06%$49.26 - $60.16 $ 73.0436%105750
Scott Black 2012-06-30 Reduce -23.13%0.06%$49.26 - $60.16 $ 73.0436%21271
Joel Greenblatt 2012-06-30 Add 80.81%0.03%$49.26 - $60.16 $ 73.0436%15013
Premium More recent guru trades are included for Premium Members only!!

Guru Investment Theses on Baxter International Inc.

Diamond Hill Capital Comments on Baxter International - Oct 24, 2012

Medical supply manufacturer Baxter International, Inc. (BAX) reported solid second quarter results, which included strong volume and pricing in its antibody therapy. In addition, the company raised its dividend 34% and added $2 billion to its share repurchase capacity. Baxter is planning to add more capacity to break blood plasma into its component parts, which suggests the company is optimistic about future demand.

From Diamond Hill Capital's third quarter Select Fund Commentary.


Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc.

Diamond Hill Capital Comments on Baxter International
October 24, 2012
Medical supply manufacturer Baxter International, Inc. (BAX) reported solid second quarter results, which included strong volume and pricing in its antibody therapy. In addition, the company raised its dividend 34% and added $2 billion to its share repurchase capacity. Baxter is planning to add more capacity to break blood plasma into its component parts, which suggests the company is optimistic about future demand. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 17.80
BAX's P/E(ttm) is ranked higher than
83% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.40 vs. BAX: 17.80 )
BAX' s 10-Year P/E(ttm) Range
Min: 12.15   Max: 57.52
Current: 17.8
12.15
57.52
P/B 5.70
BAX's P/B is ranked lower than
79% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. BAX: 5.70 )
BAX' s 10-Year P/B Range
Min: 3.47   Max: 10.16
Current: 5.7
3.47
10.16
P/S 2.83
BAX's P/S is ranked lower than
54% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BAX: 2.83 )
BAX' s 10-Year P/S Range
Min: 1.41   Max: 4.65
Current: 2.83
1.41
4.65
PFCF 21.70
BAX's PFCF is ranked higher than
67% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.35 vs. BAX: 21.70 )
BAX' s 10-Year PFCF Range
Min: 13.01   Max: 124
Current: 21.7
13.01
124
EV-to-EBIT 14.9
BAX's EV-to-EBIT is ranked higher than
82% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.12 vs. BAX: 14.9 )
BAX' s 10-Year EV-to-EBIT Range
Min: 10   Max: 42.4
Current: 14.9
10
42.4
PEG 3
BAX's PEG is ranked higher than
86% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. BAX: 3 )
BAX' s 10-Year PEG Range
Min: 0.72   Max: 70.42
Current: 3
0.72
70.42
Shiller P/E 20.5
BAX's Shiller P/E is ranked higher than
84% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.85 vs. BAX: 20.5 )
BAX' s 10-Year Shiller P/E Range
Min: 14.67   Max: 38.68
Current: 20.5
14.67
38.68

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.31
BAX's Dividend Yield is ranked higher than
91% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. BAX: 2.31 )
BAX' s 10-Year Dividend Yield Range
Min: 0.35   Max: 3.12
Current: 2.31
0.35
3.12
Dividend Payout 0.4069
BAX's Dividend Payout is ranked higher than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.53 vs. BAX: 0.4069 )
BAX' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1.07
Current: 0.41
0.27
1.07
Dividend growth (3y) 10.1
BAX's Dividend growth (3y) is ranked higher than
96% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BAX: 10.1 )
BAX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 16.4
Current: 10.1
0
16.4
Yield on cost (5-Year) 4.29
BAX's Yield on cost (5-Year) is ranked higher than
97% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. BAX: 4.29 )
BAX' s 10-Year Yield on cost (5-Year) Range
Min: 0.65   Max: 5.83
Current: 4.29
0.65
5.83
Share Buyback Rate 2.5
BAX's Share Buyback Rate is ranked higher than
95% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -1.70 vs. BAX: 2.5 )
BAX' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -2
Current: 2.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 12.4
BAX's Price/Net Current Asset Value is ranked higher than
61% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. BAX: 12.4 )
BAX' s 10-Year Price/Net Current Asset Value Range
Min: 7.4   Max: 17.5
Current: 12.4
7.4
17.5
Price/Tangible Book 11
BAX's Price/Tangible Book is ranked higher than
88% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BAX: 11 )
BAX' s 10-Year Price/Tangible Book Range
Min: 7.3   Max: 18.8
Current: 11
7.3
18.8
Price/DCF (Projected) 1.5
BAX's Price/DCF (Projected) is ranked higher than
84% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.20 vs. BAX: 1.5 )
BAX' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 2.6
Current: 1.5
1
2.6
Price/Median PS Value 1.1
BAX's Price/Median PS Value is ranked higher than
70% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.90 vs. BAX: 1.1 )
BAX' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 1.7
Current: 1.1
0.8
1.7
Price/Peter Lynch Fair Value 2.6
BAX's Price/Peter Lynch Fair Value is ranked lower than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. BAX: 2.6 )
BAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1   Max: 2.2
Current: 2.6
1
2.2
Price/Graham Number 2.9
BAX's Price/Graham Number is ranked higher than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. BAX: 2.9 )
BAX' s 10-Year Price/Graham Number Range
Min: 2.2   Max: 5.9
Current: 2.9
2.2
5.9
Earnings Yield (Greenblatt) 6.70
BAX's Earnings Yield (Greenblatt) is ranked higher than
89% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BAX: 6.70 )
BAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 10
Current: 6.7
2.4
10
Forward Rate of Return (Yacktman) 10.24
BAX's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.11 vs. BAX: 10.24 )
BAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2   Max: 24
Current: 10.24
-2
24

Business Description

Baxter International Inc, was incorporated under Delaware law in 1931. The Company through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a healthcare Company, Baxter applies a combination of medical devices, pharmaceuticals and biotechnology to create products that patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The company operated in three segments: BioScience, Medication Delivery and Renal. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medication Delivery business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The Renal business provides products to treat end-stage renal disease, or irreversible kidney failure. The business manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy, and also distributes products for hemodialysis (HD), which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or homecare Companies. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. BioScience continues to face competitors from pharmaceutical, biotechnology and other companies. Medical Products faces competition from medical device manufacturers and pharmaceutical companies. The operations of Baxter and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, COV, TMO, COO, ISRG
Traded in other countries:BAX.Switzerland, BTL.Germany
ยป More Articles for BAX

Headlines

Articles On GuruFocus.com
7 Dividend Stocks Sending More Cash to Shareholders May 13 2013 
My 3 Favorite Stocks With A Dividend Growth From Last Week May 12 2013 
Medtronic Inc. (MDT) Dividend Stock Analysis Mar 29 2013 
The Best Yielding Ex-Dividend Stocks On March 06, 2013 Mar 05 2013 
Next Week's Best Yielding Ex-Dividend Stocks March 4 - 10, 2013 Mar 04 2013 
Guru Stocks at 52-Week Highs: CMCSA, DE, CPB, and BAX Jan 28 2013 
Baxter International Inc: Fundamental Stock Research Analysis Jan 16 2013 
The Unbridled Truth About Dividends' Contribution to Shareholder Profitability Nov 27 2012 
Diamond Hill Capital Comments on Baxter International Oct 24 2012 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 21 2012 

More From Our Partners
Tiffany Hikes Dividend - Analyst Blog May 17 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial